• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of hypertension >Treatment with calcium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-European population: results from STEPHY II. Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (see comments)
【24h】

Treatment with calcium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-European population: results from STEPHY II. Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (see comments)

机译：使用钙拮抗剂的治疗不会增加欧洲中部老年人的致命或非致命癌症的风险：STEPHY II的结果。斯塔恩伯格老年人帕金森病和高血压流行病学研究（见评论）

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To assess the relationship between use of calcium antagonists and incidence of fatal or non-fatal cancer over 3 years in the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY) population. DESIGN: A prospective cohort study with follow-up analysis after 3 years. PATIENTS AND METHODS: In 1992 STEPHY workers investigated the total population aged > 65 years (n = 1190) of two villages in Bavaria, Germany. With 982 participants (response rate 83%) the prevalence of 'actual' hypertension (blood pressure > or = 160/95 mmHg or treatment) was 53%. Of all hypertensives (n = 491), 54% were being treated, 28% (n = 137) with calcium antagonists. Participants with a history of cancer or manifest cancer were excluded from further analysis. In 1995 in STEPHY II, the 3-year follow-up, we assessed total mortality (including cases of fatal cancer), cardiovascular events and cases of non-fatal cancer between 1992 and 1995. The evaluation included a second interview, use of case records of general practitioners and hospitals and analysis of the official death certificates. The total incidence of fatal and non-fatal cancer (a combined end point) was calculated for participants treated with calcium antagonists and those not taking calcium antagonists. RESULTS: Total mortality over 3 years was 12.1 % (n = 119). There were 22 deaths due to cancer and 75 cases of newly diagnosed non-fatal cancer. The combined incidence of fatal and non-fatal cancer (primary end point) was 10.9% (n = 15) for participants treated with calcium antagonists and 9.7% (n = 82) for those not taking calcium antagonists (odds ratio 1.12, 95% confidence interval 0.7-1.8). There was also no significant difference between the incidences of fatal cancer (2.2% in both groups), non-fatal cancer (12.5% for participants treated with calcium antagonists and 10.8% for those not taking calcium antagonists) and total mortality (14.6% for participants taking calcium antagonists and 11.7% for those not treated with calcium antagonists). CONCLUSION: Use of calcium antagonists does not increase the risk of fatal or non-fatal cancer over 3 years in an elderly mid-European population.
机译：目的：在Starnberg老年帕金森病和高血压流行病学研究（STEPHY）中，评估使用钙拮抗剂与致命或非致命癌症发生率之间的关系。设计：一项前瞻性队列研究，三年后进行随访分析。患者和方法：1992年，STEPHY工人调查了德国巴伐利亚州两个村庄的65岁以上（n = 1190）的总人口。 982名参与者（响应率83％）的“实际”高血压（血压>或= 160/95 mmHg或治疗）的患病率为53％。在所有高血压患者中（n = 491），正在接受钙拮抗剂治疗的比例为54％，其中28％（n = 137）。具有癌症病史或明显癌症的参与者被排除在进一步分析之外。 1995年，在为期3年的STEPHY II中，我们评估了1992年至1995年之间的总死亡率（包括致命癌症病例），心血管事件和非致命癌症病例。评估包括第二次访谈，病例使用全科医生和医院的记录以及官方死亡证明的分析。计算了接受钙拮抗剂治疗的参与者和未服用钙拮抗剂的参与者的致命和非致命癌症的总发生率（联合终点）。结果：3年总死亡率为12.1％（n = 119）。有22例因癌症死亡和75例新诊断的非致命癌症。接受钙拮抗剂治疗的参与者的致命和非致死性癌症的总发生率（主要终点）为10.9％（n = 15），而未接受钙拮抗剂的参与者的总发生率为9.7％（n = 82）（优势比为1.12，95％）置信区间0.7-1.8）。致命癌症的发生率（两组均为2.2％），非致命癌症的发生率（接受钙拮抗剂治疗的参与者为12.5％，未接受钙拮抗剂的参与者为10.8％）和总死亡率（发生率分别为14.6％）之间没有显着差异。参与者服用钙拮抗剂，未使用钙拮抗剂的参与者为11.7％）。结论：在欧洲中部老年人群中，使用钙拮抗剂并不会增加3年以上致命或非致命癌症的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号